Advicenne draws €1M bond tranche, extending runway to 2028
What's the deal? Advicenne, a Paris-based pharmaceutical company developing treatments for rare kidney diseases, has received the remaining tranche of a bond financing, a net €1 million under an agreement with a fund managed by L1 CapitalDealroom has a profile for this one. Try Dealroom →. The post-IPO convertible drawdown lifts the company's cash position and pushes its financial runway to 2028.
Why now? The financing was provided for under Advicenne's safeguard plan, giving the company a buffer amid market uncertainty. Its cash stood at €1.55 million as of June 30, 2026.
What's the endgame? The extension to 2028 — up from a previously estimated second quarter of 2027 — is also underpinned by sales of its products. The company cited strong performance from Likozam and Levidcen in France and Sibnayal across its markets.
Advicenne's lead product, Sibnayal, has marketing approval for distal renal tubular acidosis in the EU, UK, Saudi Arabia, and UAE, and is sold in more than 25 countries.
What could go wrong? Because the bonds' conversion price depends on the share price, the number of shares issued on conversion is undetermined. That conversion "may therefore result in significant dilution for existing shareholders," the company said.
Advicenne also holds the option to draw an additional €1.2 million made available by long-standing shareholder Cemag InvestDealroom has a profile for this one. Try Dealroom →, Europe OfferingDealroom has a profile for this one. Try Dealroom →, and chief executive officer Didier Laurens.
The signal: "This financing, provided for under the safeguard plan, enables us to secure our cash needs in a context of uncertainty in the financial markets," Laurens said. For a small-cap specialty drugmaker, buying time through 2028 while sales climb is the difference between funding operations and returning to the market on weaker terms.
Read more: wallstreet-online.de
Image credit: zhouxuan12345678
